By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Sunovion Pharmaceuticals Inc. 

84 Waterford Drive

Marlborough  Massachusetts  01752  U.S.A.
Phone: 508-481-6700 Fax:


SEARCH JOBS




Collaborations

ACADIA Pharmaceuticals, Inc.  ACADIA has formed a broad CNS collaboration with Sepracor for the discovery and development of new drug candidates against muscarinic receptors.

Cubist Pharmaceuticals, Inc. 





Company News
PsychoGenics Inc. Achieves Another Milestone In Drug Discovery Collaboration With Sunovion Pharmaceuticals Inc. 1/27/2015 8:06:52 AM
Sunovion Pharmaceuticals Inc. Files Patent Infringement Lawsuits Regarding Latuda® 1/15/2015 10:12:39 AM
Sunovion Pharmaceuticals Inc. Announces FDA Acceptance For Review Of Supplemental New Drug Application For The Use Of AptiomĀ® (Eslicarbazepine Acetate) As Monotherapy Treatment For Partial-Onset Seizures 1/7/2015 10:35:59 AM
Sunovion Pharmaceuticals Inc. Release: Investigational Drug Dasotraline Significantly Improved Symptoms Of Attention Deficit Hyperactivity Disorder (ADHD) In A Placebo-Controlled Study In Adults 12/11/2014 8:14:35 AM
Sunovion Pharmaceuticals Inc. Submits Supplemental New Drug Application Seeking Approval For The Use Of Aptiom® (Eslicarbazepine Acetate) As Monotherapy Treatment For Partial-Onset Seizures 12/5/2014 9:08:25 AM
Sunovion Pharmaceuticals Inc. And The COPD Foundation Expand COPD Together Campaign To Empower Family Caregivers 11/5/2014 10:43:47 AM
ex scientia Ltd. Partners With Sunovion Pharmaceuticals Inc. To Research New Medicines For Psychiatric Disorders 11/4/2014 10:30:31 AM
CHEST, Sunovion Pharmaceuticals Inc. Encourage COPD Education Among Hispanics During COPD Awareness Month 11/3/2014 9:23:55 AM
Sunovion Pharmaceuticals Inc. Announces Dose Ranging Data From Phase 2 Study Of SUN-101 (Glycopyrrolate) Inhalation Solution For Treatment Of Patients With Moderate-To-Severe Chronic Obstructive Pulmonary Disease (COPD) 10/27/2014 3:04:46 PM
Akorn, Inc. (AKN) Ponies Up $45 Million Cash For Sunovion Pharmaceuticals Inc.'s Xopenex® (levalbuterol HCI) Inhalation Solution 10/1/2014 5:53:07 AM
12345678910...
//-->